Womenra: Restore Female Sexual Desire with Flibanserin
Womenra
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.00 | $50.00 (0%) | 🛒 Add to cart |
| 20 | $3.00 | $100.00 $60.00 (40%) | 🛒 Add to cart |
| 30 | $2.33 | $150.00 $70.00 (53%) | 🛒 Add to cart |
| 60 | $1.50 | $300.00 $90.00 (70%) | 🛒 Add to cart |
| 90 | $1.22 | $450.00 $110.00 (76%) | 🛒 Add to cart |
| 120 | $1.17 | $600.00 $140.00 (77%) | 🛒 Add to cart |
| 180 | $1.00 | $900.00 $180.00 (80%) | 🛒 Add to cart |
| 270 | $0.89 | $1350.00 $240.00 (82%) | 🛒 Add to cart |
| 360 | $0.83
Best per pill | $1800.00 $300.00 (83%) | 🛒 Add to cart |
Womenra is a prescription medication specifically developed to address acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It contains the active ingredient flibanserin, a multifunctional serotonin agonist and antagonist that works centrally to rebalance neurotransmitters associated with sexual interest. Unlike situational or relationship-related decreases in libido, HSDD is characterized by a persistent absence of sexual fantasies and desire that causes marked distress or interpersonal difficulty. This non-hormonal, daily oral treatment represents a clinically validated approach to restoring satisfying sexual activity and improving emotional well-being. It is intended for use under medical supervision as part of a comprehensive treatment plan.
Features
- Active ingredient: Flibanserin 100 mg
- Formulation: Oral tablet
- Mechanism: Central serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist
- Administration: Once daily at bedtime
- Prescription status: Rx-only medication
- Non-hormonal mode of action
- Clinically studied in premenopausal women
Benefits
- Increases the number of satisfying sexual events (SSEs) per month
- Reduces distress associated with low sexual desire
- Improves sexual desire scores as measured by validated patient-reported outcomes
- Provides a non-hormonal treatment option for HSDD
- May enhance emotional satisfaction with sexual relationship
- Supports overall sexual well-being and quality of life
Common use
Womenra is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). HSDD is characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. The disorder must be acquired (developing in a patient who previously had no problems with sexual desire) and generalized (not situational or partner-specific). Treatment should be initiated and supervised by a healthcare provider experienced in managing female sexual dysfunction.
Dosage and direction
The recommended dosage is 100 mg taken orally once daily at bedtime. Administration at bedtime is recommended to minimize the risk of hypotension, syncope, central nervous system depression, and other adverse reactions. Tablets should be swallowed whole with water and not crushed, chewed, or broken. Womenra may be taken with or without food, but consistent administration relative to meals is advised. Dose adjustment is not recommended based on age, race, or renal impairment. The medication requires daily administration to maintain therapeutic effect; it is not intended for use on an as-needed basis. Treatment response should be evaluated after 8 weeks of continuous therapy.
Precautions
Womenra carries important safety considerations that require careful patient selection and monitoring. It is contraindicated with moderate or strong CYP3A4 inhibitors and in patients with hepatic impairment. Blood pressure should be monitored within 6 hours of the first dose and periodically thereafter. Patients should be advised about the potential for hypotension, syncope, and central nervous system depression. Alcohol consumption is contraindicated during treatment due to increased risk of severe hypotension and syncope. Caution is advised when prescribing to patients with low blood pressure or those taking medications that can lower blood pressure. The risk of somnolence may impair ability to drive or operate machinery, particularly within 6 hours of administration.
Contraindications
Womenra is contraindicated in the following circumstances: concomitant use with moderate or strong CYP3A4 inhibitors; hepatic impairment; concomitant use with alcohol; hypersensitivity to flibanserin or any component of the formulation; and concomitant use with other central nervous system depressants. It is not indicated for use in postmenopausal women or men, and should not be used in patients with a history of hypotension or syncope. Concomitant use with fluconazole (a moderate CYP3A4 inhibitor) is specifically contraindicated.
Possible side effects
The most common adverse reactions (≥2% incidence and greater than placebo) include: dizziness (11.4%), somnolence (11.2%), nausea (8.3%), fatigue (7.5%), insomnia (4.9%), dry mouth (3.2%), and anxiety (2.1%). Serious adverse reactions include hypotension, syncope, and central nervous system depression. Approximately 13% of patients discontinued treatment due to adverse reactions, compared to 6% with placebo. The incidence of syncope was 0.4% with Womenra versus 0.2% with placebo. Patients should be monitored for signs of hypotension and advised to report any episodes of dizziness, lightheadedness, or loss of consciousness.
Drug interaction
Womenra is primarily metabolized by CYP3A4 and CYP2C19 enzymes, resulting in significant drug interaction potential. Concomitant use with moderate or strong CYP3A4 inhibitors is contraindicated. These include: ketoconazole, itraconazole, clarithromycin, ritonavir, conivaptan, and grapefruit juice. Concomitant use with CYP2C19 inhibitors may increase flibanserin exposure. Womenra may enhance the effects of CNS depressants including alcohol, benzodiazepines, opioids, and sedating antihistamines. Concurrent use with medications that affect blood pressure may potentiate hypotensive effects. Healthcare providers should conduct a comprehensive medication review before initiation and during treatment.
Missed dose
If a dose is missed, patients should skip the missed dose and take the next dose at the regular time the following bedtime. Patients should not take two doses on the same day to make up for a missed dose. Doubling the dose may increase the risk of adverse reactions including hypotension and syncope. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy. Consistent daily administration is important for maintaining therapeutic effect.
Overdose
In case of suspected overdose, immediate medical attention should be sought. Symptoms may include severe hypotension, syncope, sedation, and other manifestations of excessive CNS depression. There is no specific antidote for flibanserin overdose. Treatment should consist of supportive measures including continuous blood pressure monitoring and appropriate management of hypotension. Gastric lavage or administration of activated charcoal may be considered if presented soon after ingestion. Hemodialysis is not expected to be effective due to high protein binding. Patients should be monitored for at least 24 hours due to the prolonged half-life of the medication.
Storage
Store at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not transfer tablets to other containers, as this may affect stability. Protect from light and excessive humidity. Discard any medication that appears discolored or shows signs of deterioration.
Disclaimer
Womenra is available by prescription only and should be used under the supervision of a qualified healthcare provider. This information is provided for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Individual results may vary. Patients should discuss their medical history, current medications, and treatment options with their healthcare provider. The medication is not intended for use in postmenopausal women, men, or adolescents. Safety and effectiveness have not been established in these populations. Patients should report any adverse reactions to their healthcare provider.
Reviews
Clinical trials demonstrated that Womenra significantly increased the number of satisfying sexual events (SSEs) per month compared to placebo (4.5 vs 3.7, p<0.0001) and improved sexual desire scores. In patient-reported outcomes, 46% of women treated with Womenra reported meaningful improvement in sexual desire versus 29% with placebo. Many patients reported decreased distress related to their sexual desire concerns. Real-world evidence suggests that women who respond to treatment typically notice improvement within 4-8 weeks of consistent use. Patient satisfaction surveys indicate that successful treatment correlates with improved relationship satisfaction and overall quality of life. However, individual responses vary, and some patients may not experience significant benefit.